0001209191-19-061579.txt : 20191220 0001209191-19-061579.hdr.sgml : 20191220 20191220164116 ACCESSION NUMBER: 0001209191-19-061579 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191218 FILED AS OF DATE: 20191220 DATE AS OF CHANGE: 20191220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sandison Taylor CENTRAL INDEX KEY: 0001702287 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 191302097 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-18 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001702287 Sandison Taylor 6310 NANCY RIDGE DR, SUITE 101 SAN DIEGO CA 92121 0 1 0 0 Chief Medical Officer Employee Stock Option (right to buy) 13.62 2019-12-18 4 D 0 19000 D 2025-10-29 Common Stock 19000 0 D Employee Stock Option (right to buy) 2.45 2019-12-18 4 A 0 12667 A 2026-12-17 Common Stock 12667 12667 D Employee Stock Option (right to buy) 9.89 2019-12-18 4 D 0 5000 D 2026-03-15 Common Stock 5000 0 D Employee Stock Option (right to buy) 2.45 2019-12-18 4 A 0 3333 A 2026-12-17 Common Stock 3333 3333 D Employee Stock Option (right to buy) 11.11 2019-12-18 4 D 0 20000 D 2026-08-31 Common Stock 20000 0 D Employee Stock Option (right to buy) 2.45 2019-12-18 4 A 0 13333 A 2026-12-17 Common Stock 13333 13333 D Employee Stock Option (right to buy) 7.80 2019-12-18 4 D 0 55000 D 2027-03-30 Common Stock 55000 0 D Employee Stock Option (right to buy) 2.45 2019-12-18 4 A 0 32592 A 2026-12-17 Common Stock 32592 32592 D Employee Stock Option (right to buy) 2.45 2019-12-18 4 A 0 4075 A 2026-12-17 Common Stock 4075 4075 D The option provided for vesting as follows: 25% on October 13, 2016 with 1/36th of the remaining shares vesting monthly thereafter, such that all shares subject to the option were vested on October 13, 2019. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 19,000 shares of the Issuer's common stock granted to the reporting person on October 30, 2015. In exchange, the reporting person received a replacement option, for 12,667 shares, having an exercise price of $2.45 a share. The option shall vest in full on December 18, 2020. The option provided for vesting in a series of 36 monthly installments and was fully vested on March 16, 2019. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 5,000 shares of the Issuer's common stock granted to the reporting person on March 16, 2016. In exchange, the reporting person received a replacement option, for 3,333 shares, having an exercise price of $2.45 a share. The option provided for vesting in a series of 36 monthly installments and was fully vested on September 1, 2019. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 20,000 shares of the Issuer's common stock granted to the reporting person on September 1, 2016. In exchange, the reporting person received a replacement option, for 13,333 shares, having an exercise price of $2.45 a share. The option provided for vesting in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017 such that the option would have been fully vested on March 31, 2020. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 55,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 36,667 shares, having an exercise price of $2.45 a share. The option vests as follows: 1/3rd shall vest on December 18, 2020, and the balance of the shares will vest in twenty-four (24) equal monthly installments thereafter, such that all shares subject to the option shall be fully vested on December 18, 2022. /s/ Jessica Oien, Attorney-in-fact 2019-12-20